Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces today that it received a medium-term financing of 3 M€, through a bond issue.

This strengthens the cash position of the company at a time when Quantum Genomics is very close to launch its phase II clinical trials of QGC001, first in class drug candidate for the treatment of hypertension

Download press release
distribué par